Phase II study of single agent paclitaxel in adult patients with relapsed acute lymphocytic leukemia

Dawn E. Colburn; Deborah A. Thomas; Francis J. Giles

doi:10.1023/A:1022984830258

Phase II study of single agent paclitaxel in adult patients with relapsed acute lymphocytic leukemia

Dawn E. Colburn, Deborah A. Thomas, Francis J. Giles^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Background: A phase II study of paclitaxel in patients with relapsed adult acute lymphocytic leukemia (ALL) was conducted. Methods: Patients with relapsed ALL, no more than one prior salvage regimen, and no overt hepatic, renal, or cardiac dysfunction were eligible. Patients received paclitaxel 250 mg/m² given as a continuous 24 -h intravenous infusion repeated every 3-4 weeks. Results: Eight patients received 13 courses of paclitaxel. One transient partial response was observed. The only severe extramedullary toxicities observed were Grade 3 myalgias and arthralgias. Conclusion: The study paclitaxel regimen was ineffective in refractory adult ALL.

Original language	English (US)
Pages (from-to)	109-111
Number of pages	3
Journal	Investigational New Drugs
Volume	21
Issue number	1
DOIs	https://doi.org/10.1023/A:1022984830258
State	Published - Feb 2003

Keywords

Acute lymphocytic leukemia
Adult
Paclitaxel
Refractory

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1023/A:1022984830258

Cite this

@article{4a8fad3279e1442ca685fe2c9fdc3aa6,

title = "Phase II study of single agent paclitaxel in adult patients with relapsed acute lymphocytic leukemia",

abstract = "Background: A phase II study of paclitaxel in patients with relapsed adult acute lymphocytic leukemia (ALL) was conducted. Methods: Patients with relapsed ALL, no more than one prior salvage regimen, and no overt hepatic, renal, or cardiac dysfunction were eligible. Patients received paclitaxel 250 mg/m2 given as a continuous 24 -h intravenous infusion repeated every 3-4 weeks. Results: Eight patients received 13 courses of paclitaxel. One transient partial response was observed. The only severe extramedullary toxicities observed were Grade 3 myalgias and arthralgias. Conclusion: The study paclitaxel regimen was ineffective in refractory adult ALL.",

keywords = "Acute lymphocytic leukemia, Adult, Paclitaxel, Refractory",

author = "Colburn, {Dawn E.} and Thomas, {Deborah A.} and Giles, {Francis J.}",

year = "2003",

month = feb,

doi = "10.1023/A:1022984830258",

language = "English (US)",

volume = "21",

pages = "109--111",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "1",

}

TY - JOUR

T1 - Phase II study of single agent paclitaxel in adult patients with relapsed acute lymphocytic leukemia

AU - Colburn, Dawn E.

AU - Thomas, Deborah A.

AU - Giles, Francis J.

PY - 2003/2

Y1 - 2003/2

N2 - Background: A phase II study of paclitaxel in patients with relapsed adult acute lymphocytic leukemia (ALL) was conducted. Methods: Patients with relapsed ALL, no more than one prior salvage regimen, and no overt hepatic, renal, or cardiac dysfunction were eligible. Patients received paclitaxel 250 mg/m2 given as a continuous 24 -h intravenous infusion repeated every 3-4 weeks. Results: Eight patients received 13 courses of paclitaxel. One transient partial response was observed. The only severe extramedullary toxicities observed were Grade 3 myalgias and arthralgias. Conclusion: The study paclitaxel regimen was ineffective in refractory adult ALL.

AB - Background: A phase II study of paclitaxel in patients with relapsed adult acute lymphocytic leukemia (ALL) was conducted. Methods: Patients with relapsed ALL, no more than one prior salvage regimen, and no overt hepatic, renal, or cardiac dysfunction were eligible. Patients received paclitaxel 250 mg/m2 given as a continuous 24 -h intravenous infusion repeated every 3-4 weeks. Results: Eight patients received 13 courses of paclitaxel. One transient partial response was observed. The only severe extramedullary toxicities observed were Grade 3 myalgias and arthralgias. Conclusion: The study paclitaxel regimen was ineffective in refractory adult ALL.

KW - Acute lymphocytic leukemia

KW - Adult

KW - Paclitaxel

KW - Refractory

UR - http://www.scopus.com/inward/record.url?scp=0038353443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038353443&partnerID=8YFLogxK

U2 - 10.1023/A:1022984830258

DO - 10.1023/A:1022984830258

M3 - Article

C2 - 12795536

AN - SCOPUS:0038353443

SN - 0167-6997

VL - 21

SP - 109

EP - 111

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 1

ER -

Phase II study of single agent paclitaxel in adult patients with relapsed acute lymphocytic leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this